Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

Although docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist. METHODS: Between September 21, 2005, and January 13, 2015, we randomly assigned 350 men 1:1 with T1...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Amico, Anthony V., Xie, Wanling, McMahon, Elizabeth, Loffredo, Marian, Medeiros, Shana, Joseph, David, Denham, Jim, Kumar, Parvesh, Bubley, Glenn, Sullivan, Molly, Hellwig, Richard, Carlos Vera, Juan, Freter, Rolf, Jeffrey Baker, W., Wong, Jeffrey Y., Renshaw, Andrew A., Kantoff, Philip W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425842/
https://www.ncbi.nlm.nih.gov/pubmed/34197181
http://dx.doi.org/10.1200/JCO.21.00596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425842/
https://www.ncbi.nlm.nih.gov/pubmed/34197181
http://dx.doi.org/10.1200/JCO.21.00596

Ejemplares similares